Journal of Cardiovascular Disease Research

ISSN: 0975-3583,0976-2833 VOL02, ISSUE 01, 2011

Retina Vascular Diseases: A Comprehensive Review

Dr Krishna Kuldeep
Assistant professor, Department of Ophthalmology, VCSG Government Medical College, Srinagar, Pauri Garhwal, Uttarakhand
Corresponding author Email id: drkkgupta1@gmail.com

Abstract
Vascular diseases of the retina are conditions that affect the retina's blood vessels; light-sensitive tissue at the back of the eye. If left untreated, these disorders may cause severe impairment of eyesight or even total blindness. Diabetic retinopathy (DR), retinal vein occlusion (RVO), retinal artery occlusion (RAO), macular degeneration, & hypertensive retinopathy are the most prevalent vascular disorders of the retina. Medication, laser surgery, or other techniques to reduce swelling, halt bleeding, or prevent additional damage to the retina are only some of the treatment options available. To avoid irreversible vision loss, it is essential to have regular eye examinations so that these disorders may be detected & treated early. This review paper highlights the molecular pathogenesis along with regular treatment methods of various Retina Vascular diseases (RVDs) briefly. per.
Keywords: *Retina Vascular Diseases; Molecular Pathogenesis; Treatment Methods*

1. Introduction

Disorders affecting retinal blood vessels, the light-sensitive tissue in the back of the eye, are collectively known as vascular disorders of the retina. If these disorders aren't addressed, they may lead to impaired eyesight or possibly total blindness. DR, a consequence of diabetes that destroys retinal blood vessels, is one of the most frequent vascular disorders of the retina. [1]. Blood vessels may leak fluid or blood, causing swelling or bleeding in the retina. In severe cases, the retina may detach, leading to permanent vision loss. RVO, this condition occurs when a blood clot blocks one of the veins that carries blood away from the retina [2]. This can cause bleeding, swelling, & fluid buildup in the retina, leading to vision loss. When one of the arteries supplying blood to the retina becomes blocked by a clot, the condition is known as RAO. As a result, there may be a sudden loss of vision, which is commonly compared to a "curtain falling" over the affected eye. Degeneration of the macula, the area of the retina most important for crisp, detailed vision, is known as macular degeneration. [3]. In some cases, the blood vessels in the macula may leak, leading to fluid buildup & vision loss. High blood pressure, often known as hypertensive retinopathy, is a disorder in which the retina's blood vessels get damaged. It can cause bleeding, swelling, & fluid buildup, leading to vision loss. Treatment for these conditions may include medications, laser surgery, or other procedures aimed at reducing swelling, stopping bleeding, or preventing further damage to the retina [4]. Regular eye examinations are necessary for the early diagnosis & treatment of these disorders to avoid blindness. Visual impairment is frequently caused by retinal & choroidal vascular disorders. Neovascular AMD, often known as nAMD, is the most prevalent choroidal vascular disease. As the world's population ages, AMD incidence is predicted to rise to 288 million by 2040, from an estimated 196 million in 2020[5]. Neovascularization (NV) affects about 10% of AMD patients, making it a common condition. With a frequency of 16.4 million worldwide in 2008, RVO is the second most prevalent RVD, & a significant number of RVO patients experience macular edoema [6]. These three illnesses are the leading causes of acute & intermediate vision loss across the world. This review article provides a concise discussion of the molecular pathophysiology, as well as the standard & advanced therapy options for, many disorders of the retinal vasculature.

ISSN: 0975-3583,0976-2833 VOL02, ISSUE 01, 2011

2. Fundamental Concept of Disease

Retinal vascular disorders are a leading cause of blindness & visual impairment. Retinal blood vessel damage, caused by several illnesses, may impair vision [7]. DR, RVO, RVA, macular degeneration, & hypertensive retinopathy are the most prevalent vascular disorders of the retina. The most prevalent RVD, DR, results from high blood sugar levels damaging retinal blood vessels [8]. Blood clots cause RVO & RAO, both of which prevent blood from flowing to & from the retina, respectively [9]. Degeneration of the macula, the retinal area responsible for centre vision & fine detail, may cause blindness [10]. High blood pressure causes hypertensive retinopathy by damaging retinal blood vessels. Treatment for these conditions includes medication, laser surgery, or other procedures aimed at reducing swelling, stopping bleeding, or preventing further damage to the retina [11]. Permanent visual loss may be avoided with early identification & treatment, making regular eye exams crucial for individuals at risk for these conditions. In summary, vascular diseases of the retina are a significant cause of vision loss, & one must know the risk factors, symptoms, & treatment options to prevent permanent damage to the eye.

3. Retina Vascular Diseases -Pathogenesis

Retina vascular diseases refer to a group of conditions that affect the blood vessels that supply oxygen & nutrients to the retina, the light-sensitive tissue at the back of the eye. The pathogenesis of these diseases involves various factors, including inflammation, oxidative stress (OS), & altered blood flow. DR is a severe complication of diabetes that affects the retinal blood vessels & is a significant cause of blindness globally. Damage to the retinal blood vessels from high blood sugar levels over a long period of time causes DR, which manifests itself first as a leakage of blood & fluid into the retina & then as the growth of aberrant new blood vessels. These developing blood vessels are delicate, & a rupture might cause bleeding into the vitreous gel & eventual blindness [12]. AMD is another RVD that affects adults over the age of 50 & causes vision loss. The macua, the retinal area in the centre responsible for centre vision & fine detail, is damaged by AMD. It is unclear what causes AMD, however OS, inflammation, & genetics are likely contributors to the disease's aetiology. RVO is another RVD that occurs when a vein carrying blood away from the retina is obstructed, leading to bleeding & fluid leakage in the retina. This can in vision loss, depending on the location & extent of the blockage. RVO's pathogenesis is multifactorial & can involve factors such as hypertension, diabetes, & atherosclerosis. Hypertensive retinopathy is a RVD that happens because of chronic high blood pressure. The pathogenesis involves the narrowing of the retinal blood vessels, leading to decreased blood flow & the formation of small, rounded bulges called microaneurysms [13]. This can eventually lead to retinal swelling & vision loss. Overall, the pathogenesis of RVDs involves complex interactions between various factors, including inflammation, OS, altered blood flow, & underlying medical conditions such as diabetes & hypertension. Different types of RVDs are discussed in the following section briefly.:

3.1 Diabetic Retinopathy-Molecular Pathogenesis

This is a RVD that develops as a diabetes mellitus complication. The pathogenesis of DR is complex & multifactorial, involving a wide range of molecular & cellular mechanisms [14]. Pathogenesis of DR is influenced by a number of molecular pathways, including:

- Hyperglycemia-induced oxidative stress: Chronic hyperglycemia (high blood sugar levels) leads to the creation of reactive oxygen species (ROS) & OS in retinal cells. This OS has the potential to disrupt biological processes & even cause cell death by damaging lipids, proteins & DNA.
- Inflammatory pathways: Retinal cells may have their inflammatory pathways activated by hyperglycemia, resulting in the release of cytokines & chemokines that promote inflammation. The activation of leukocytes & the migration of other immune cells to the retina may be exacerbated by these chemicals, making the underlying retinal inflammation worse.

ISSN: 0975-3583,0976-2833 VOL02, ISSUE 01, 2011

- Vascular dysfunction: Hyperglycemia-induced OS & inflammation can also impair the function of retinal blood vessels. This can lead to the development of leaky blood vessels, abnormal angiogenesis, & impaired blood flow to the retina.
- Extracellular matrix (ECM) remodeling: ECM proteins; collagen & fibronectin, play a vital role in maintaining the structural integrity of retinal tissues. However, hyperglycemia can lead to the abnormal deposition & remodeling of ECM proteins, leading to the formation of fibrotic tissue in the retina.
- Neurodegeneration: DR is also linked with the degeneration of retinal neurons, including photoreceptors & ganglion cells. The exact mechanisms underlying this neurodegeneration are not fully understood but may involve hyperglycemia-induced OS, inflammation, & vascular dysfunction.

Overall, the pathogenesis of DR involves a complex interplay of various molecular mechanisms, including OS, inflammation, vascular dysfunction, ECM remodeling, & neurodegeneration. Comprehending these mechanisms is critical for developing effective treatments & preventative strategies for DR.

3.2 Retinal vein occlusion (RVO) –Molecular Pathogenesis

This is a RVD characterized by the blockage of a retinal vein, leading to fluid accumulation & bleeding in the retina. The molecular pathogenesis of RVO involves several factors, including inflammation, thrombosis, & OS. Inflammatory pathways: Inflammation plays a crucial role in RVO's pathogenesis [15]. Inflammatory cytokines & chemokines are produced in the retina in response to the obstruction of the retinal vein, leading to the recruitment & activation of immune cells; leukocytes & microglia. Retinal edoema & haemorrhage are complications that might arise from the inflammatory reaction to an RVO. Thrombosis is the obstruction of a retinal vein in RVO can lead to the activating the coagulation cascade, resulting in blood clot formation in the vein. These clots can further obstruct the vein, exacerbating the damage caused by the RVO. Factors such as increased blood viscosity, altered blood flow, & endothelial dysfunction can contribute to developing thrombosis in RVO. OS is the blockage of a retinal vein in RVO can also lead to OS in the retina. The cellular components lipids, proteins, & DNA may be damaged by reactive oxygen species produced in the ischemia environment caused by the blockage. This OS may increase the risk of edoema & retinal haemorrhage, complications of RVO. Vascular endothelial growth factor (VEGF) & other growth factors are crucial in RVO's pathogenesis. VEGF is produced in response to hypoxia & inflammation & can add to developing neovascularization & edoema in the retina. Overall, the molecular pathogenesis of RVO involves complex interactions between various factors, including inflammation, thrombosis, OS, & growth factors. Comprehending these mechanisms is critical for developing effective treatments & preventative strategies for RVO.

3.3 Retinal artery occlusion (RAO)-Molecular Pathogenesis

This is a RVD that occurs when the central retinal artery or one of its branches becomes blocked, leading to ischemia & damage to the retina. The molecular pathogenesis of RAO involves several factors, including inflammation, thrombosis, & OS [16].

- Inflammatory pathways: Inflammation plays a crucial role in RAO pathogenesis. Inflammatory cytokines & chemokines are produced in the retina in response to the obstruction of the retinal artery, resulting in the recruitment & activation of immune cells; leukocytes & microglia. Retinal edoema & ischemia might be further exacerbated by the inflammatory reaction that follows RAO.
- Thrombosis: The obstruction of a retinal artery in RAO can lead to activating the coagulation cascade, resulting in blood clot formation in the artery. These clots can further obstruct the artery, exacerbating the damage caused by the RAO. Factors such as increased blood viscosity, altered blood flow, & endothelial dysfunction can contribute to developing thrombosis in RAO.

ISSN: 0975-3583,0976-2833 VOL02, ISSUE 01, 2011

- Oxidative stress: The blockage of a retinal artery in RAO can also lead to OS in the retina. The cellular components lipids, proteins, & DNA may be damaged by reactive oxygen species produced in the ischemia environment caused by the blockage. This OS may worsen RAO-related retinal damage by fostering the growth of edoema & ischemia.
- Growth factors: The aetiology of RAO is heavily influenced by growth elements like VEGF. Retinal neovascularization & edoema may progress in response to hypoxia & inflammation, both of which trigger the production of VEGF.

Overall, the molecular pathogenesis of RAO involves complex interactions between various factors, including inflammation, thrombosis, OS, & growth factors. Comprehending these mechanisms is critical for developing effective treatments & preventative strategies for RAO.

3.4 Age-related macular degeneration (AMD)-Molecular Pathogenesis

This is a common retinal disorder that affects the macula, the central portion of the retina responsible for detailed vision. The molecular pathogenesis of AMD involves several factors, including inflammation, OS, & dysregulation of the complement system.

- Inflammatory pathways: The function of inflammation in the development of AMD is crucial. Retinal inflammation is caused by the release of inflammatory cytokines & chemokines in response to changes caused by age & cellular stress, which then attract & activate immune cells like macrophages & microglia. This inflammatory response can exacerbate the damage caused by AMD & contribute developing drusen, hallmark lesion of early AMD.
- Oxidative stress: Given its elevated metabolic activity & exposure to light, the macula is especially vulnerable to OS. Damage to biological components including lipids, proteins, & DNA may result from OS-related buildup of ROS in the retina. Retinal pigment epithelial (RPE) cells are essential to maintaining retinal health, & because of this damage, drusen may develop, & RPE cells may die.
- Dysregulation of the complement system: A vital part of the immune system, the complement system aids in the elimination of waste & harmful microorganisms. The pathophysiology of AMD may include complement system dysregulation. Genetic polymorphisms in complement-system genes, in particular, have been linked to an elevated likelihood of developing AMD. Chronic inflammation & RPE cell injury may result from complement system dysregulation, which in turn contributes to developing age-related macular degeneration.
- Other factors: Other factors involved in AMD pathogenesis include angiogenesis & lipofuscin accumulation. Angiogenesis, or new blood vessel formation, can contribute to the development of neovascular AMD, a more advanced & severe form of the disease. Lipofuscin is a waste product that accumulates in RPE cells with age & can contribute to cellular damage & inflammation in the retina.

Overall, the molecular pathogenesis of AMD involves complex interactions between various factors, including inflammation, OS, dysregulation of the complement system, angiogenesis, & lipofuscin accumulation. Comprehending these mechanisms is critical for developing effective treatments & preventative strategies for AMD.

3.5 Hypertensive retinopathy (HR)-Molecular Pathogenesis

This is a retinal disorder that occurs as a result of chronic high blood pressure. The molecular pathogenesis of HR involves several factors, including inflammation, OS, & dysregulation of the RAS. Inflammatory pathways: The pathophysiology of HR is heavily dependent on inflammation. Chronic high blood pressure leads to endothelial dysfunction & inflammation in the retinal vasculature. This inflammation can lead to the activation of immune cells such as leukocytes & microglia, further exacerbating the damage caused by HR.

ISSN: 0975-3583,0976-2833 VOL02, ISSUE 01, 2011

- Oxidative stress: Injury to cell parts; lipids, proteins, & DNA may lead to OS in the retina from chronically high blood pressure. This OS has been linked to retinal vascular inflammation & endothelial impairment.
- Dysregulation of the renin-angiotensin system: The RAS is crucial in controlling blood pressure & maintaining fluid equilibrium. RAS dysregulation has been implicated in the pathogenesis of HR. The angiotensin II type 1 receptor (AT1R) has been singled out as a potential contributor to HR. Endothelial dysfunction, inflammation, & OS abnormalities are all brought about by AT1R activation, which all play a role in the progression of HR.
- Other factors: Other factors that have been implicated in the pathogenesis of HR include angiogenesis & the accumulation of extracellular matrix (ECM) proteins. Chronic high blood pressure can lead to forming new retinal blood vessels, contributing to the development of neovascularization & HR. Additionally, accumulation of ECM proteins in the retinal vasculature can contribute to the development of endothelial dysfunction & HR.

Overall, the molecular pathogenesis of HR involves complex interactions between various factors, including inflammation, OS, dysregulation of the RAS, angiogenesis, & ECM accumulation. Comprehending these mechanisms is critical for developing effective treatments & preventative strategies for HR.

4. Regular Treatment Method for Retinal Vascular Diseases

Here are some of the regular treatment options for different types of RVDs:

- Focal laser photocoagulation: This was a common treatment method for DR, where a laser is utilised to seal off leaking retinal blood vessels. It was also used for macular edoema & macular degeneration.
- Scatter laser photocoagulation: Utilising a laser to make tiny burns in the retina's periphery was one way to slow the development of new blood vessels that were causing problems. Proliferative DR & other retinal vascular diseases benefited from its usage.
- Corticosteroid injections: Corticosteroids are anti-inflammatory medications that were injected into the eye to reduce swelling & inflammation in the retina. They were used for diabetic macular edoema & other inflammatory conditions.
- Vitrectomy: The vitreous gel within the eye was surgically extracted, & then replaced by a saline solution. In severe instances of DR & other RVDs, it was utilised.
- Photodynamic therapy (PDT): PDT involves injecting a photosensitive medication into the bloodstream & then using a laser to activate the medication in the eye, which helps to seal off abnormal blood vessels. It was used for some types of macular degeneration.

These old treatment methods have been largely replaced by newer & more effective techniques, such as anti-VEGF therapy & newer laser treatments[17]. However, some of these old methods may still be used in certain situations or in combination with newer treatments which are discussed in the following section.

5. Developed & Emerging Treatment Method for Retinal Vascular Diseases

Several treatment methods were available to manage these conditions, including:

- Laser therapy: Laser therapy, also known as photocoagulation, is a procedure that uses a laser to destroy or seal off abnormal retinal blood vessels. This treatment is commonly used for DR & RVO.
- Intravitreal injections: Intravitreal injections involve injecting medications directly into the vitreous, the gel-like substance inside the eye, to help reduce swelling & inflammation. This treatment is commonly used for age-related macular degeneration & diabetic macular edoema.
- Anti-VEGF therapy: Anti-VEGF therapy involves injecting medications that block a protein called VEGF, which can cause abnormal blood vessels to grow & leak fluid in the retina. This treatment is commonly used for wet age-related macular degeneration.

ISSN: 0975-3583,0976-2833 VOL02, ISSUE 01, 2011

These treatment methods have been refined & improved, with the introduction of new medications & surgical techniques [18]. There are several new & emerging treatment methods for retina vascular diseases that are currently being developed & tested.

- Gene therapy: Diseases may be treated & prevented via gene therapy. Gene therapy is being investigated as a potential treatment for retinal vascular illnesses by focusing on genes & proteins known to have a role in the development of dysfunctional retinal blood vessels.
- Stem cell therapy: Stem cell therapy involves utilising stem cells to replace damaged or diseased cells in the body. Researchers are exploring the use of stem cell therapy to regenerate damaged or lost retinal cells in patients with RVDs.
- Neuroprotection therapy: Neuroprotection therapy involves using medications or other treatments to protect the nerve cells in the retina from damage or degeneration. Glaucoma & DR are two eye diseases that might benefit greatly from this strategy.
- Nanoparticle therapy: Nanoparticle therapy involves using tiny particles to deliver medications or other treatments directly to specific cells or tissues in the body. Researchers are exploring the use of nanoparticles to target & treat abnormal retinal blood vessels.
- Combination therapies: Researchers are also exploring the use of combination therapies, where two or more treatments are used together to achieve better outcomes than either treatment alone. For example, anti-VEGF therapy may be combined with laser therapy or gene therapy to enhance its effectiveness.

However, these new treatment options offer hope for improved outcomes & quality of life for patients with retina vascular diseases.

6. Conclusion

RVDs can have a significant impact on vision & quality of life, & early detection & treatment are critical for preserving vision & preventing further damage to the retina. The molecular pathogenesis of these diseases is complex & involves multiple cellular pathways & factors, making the development of effective therapies challenging. However, developed treatment options such as laser treatment, intravitreal injections, & surgery, as well as emerging therapies such as gene therapy, stem cell therapy, neuroprotection, & retinal prostheses, offer hope for the future of RVD management. Patients with RVDs should work closely with their ophthalmologist to determine the best treatment plan for their condition, & regular eye exams are essential for detecting these diseases at an early stage. Additionally, lifestyle changes such as maintaining a healthy diet & controlling blood pressure & blood sugar levels can help to reduce the risk of developing RVDs. With continued research & development, it is hopeful that new treatments will emerge, & we can improve the quality of life for those living with RVDs.

7. References

1. Ferris FL, Davis MD, Clemons TE, et al. A simplified severity scale for age-related macular degeneration: AREDS report no. 18. *Arch Ophthalmol*. 2005;123:1570–1574.
2. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: Five year results from randomized clinical trials. Arch Ophthalmol. 1991;109:1109–1114.
3. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization for subfoveal choroidal neovasculariza- tion secondary to age-related macular degeneration. Arch Ophthalmol. 1994;112:480–488.
4. Hawkins BS, Bressler NM, Miskala PH, et al. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11.

ISSN: 0975-3583,0976-2833 VOL02, ISSUE 01, 2011

Ophthalmology. 2004;111:1967–1980.

5. Bressler NM, Bressler SB, Childs AL, et al. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology. 2004;111:1993–2006.
6. Miller JW, Walsh AW, Kramer M, et al. Photodynamic ther- apy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol. 1995;113:810–818.
7. Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age- related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials- TAP report. Arch Ophthalmol. 1999;117:1329–1345.
8. N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–1309.
9. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy & other retinal disorders. N Engl J Med. 1994;331:1480–1487.
10. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF- receptor chimeric proteins. Proc Natl Acad Sci USA. 1995;92:10457–10461.
11. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization. Arch Ophthal- mol. 1996;114:66–71.
12. Okamoto N, Tobe T, Hackett SF, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal & subretinal neovascularization. Am J Pathol. 1997;151:281–291.
13. Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina. 2001;21:416–434.
14. Ohno-Matsui K, Hirose A, Yamamoto S, et al. Inducible expression of vascular endothelial growth factor in photoreceptors of adult mice causes severe prolifera- tive retinopathy & retinal detachment. Am J Pathol. 2002;160:711–719.
15. Ryan SJ. Subretinal neovascularization: natural history of an experimental model. Arch Ophthalmol. 1982;100:1804– 1809.
16. Tobe T, Ortega S, Luna JD, et al. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am J Pathol. 1998;153:1641–1646.
17. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is an important stimulator in a model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41:3158–3164.
18. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery & development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391–400.